Lupin Limited has informed the Exchange regarding a press release dated July 16, 2025, titled "Lupin Launches Loteprednol Etabonate Ophthalmic Suspension, 0.5% in the United States".
Lupin Limited has informed the Exchange regarding a press release dated July 16, 2025, titled "Lupin Launches Loteprednol Etabonate Ophthalmic Suspension, 0.5% in the United States".